Andrew Combs

Company: Prelude Therapeutics​

Job title: Chief Chemistry Officer

Seminars:

Precision ADCs: Engineering Novel Degrader Payloads for Improved Efficacy & Therapeutic Index 2:00 pm

• Explaining key design attributes required for making TPDs effective as ADC payloads • Approaching ADC payload optimization with a medicinal chemistry mindset • Sharing initial proof-of-concept with a next gen anti-PSMAxSMARCA2/4 DAC for prostate cancerRead more

day: Conference Day 2

Panel Discussion: Where do DACs Fit in? Discussing the Decision to Think about Degraders as Payloads 2:20 pm

• What is it about small molecule degraders that lend themselves to making good payloads? • Sharing parameters that allow a degrader protein to be distinct from a toxic payload • What are some good targets for DACs? • Collaboration potential between antibody engineering and protein degradation companiesRead more

day: Conference Day 2